Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Puma Biotechnology (PBYI) over the last 4 years, with Q3 2025 value amounting to -$100000.0.

  • Puma Biotechnology's Asset Writedowns and Impairment changed 0.0% to -$100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$585000.0, marking a year-over-year decrease of 78823.53%. This contributed to the annual value of -$519000.0 for FY2024, which is 15766.67% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Asset Writedowns and Impairment is -$100000.0, which was down 0.0% from -$300000.0 recorded in Q2 2025.
  • Puma Biotechnology's 5-year Asset Writedowns and Impairment high stood at $514000.0 for Q2 2023, and its period low was -$398000.0 during Q4 2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $5000.0 (2024), whereas its average is $12500.0.
  • Per our database at Business Quant, Puma Biotechnology's Asset Writedowns and Impairment plummeted by 24472.73% in 2024 and then soared by 9363.64% in 2025.
  • Quarter analysis of 3 years shows Puma Biotechnology's Asset Writedowns and Impairment stood at $275000.0 in 2023, then plummeted by 244.73% to -$398000.0 in 2024, then skyrocketed by 74.87% to -$100000.0 in 2025.
  • Its Asset Writedowns and Impairment was -$100000.0 in Q3 2025, compared to -$300000.0 in Q2 2025 and $213000.0 in Q1 2025.